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INTRODUCTION
Assessing patient's personal viewpoints on disease activity and treatment provides useful information enabling a customized therapeutic approach (1) . The pivotal role of patient's perspectives is now advocated by the Grade of Recommendations, Assessment, Development and Evaluation (GRADE) system (2) , recently adopted by the World Health Organization (WHO), as a guideline for both quality of evidence and strength of recommendations. Along with traditional parameters of safety and efficacy, this system also includes patient's preferences and values as cornerstones in the development of recommendations for therapeutic interventions, thus enabling the translation of scientific research into real life (2) . Several aspects of allergen-specific immunotherapy (SIT) for the treatment of allergic rhinitis have been extensively investigated, including clinical efficacy (3), tolerability (4), effects on health-related quality of life (HRQoL) (4-6) and cost-effectiveness (7) . However, besides HRQoL assessment, only few studies addressing patient's perspective on this treatment modality have been published (8) (9) (10) . In these studies, the population size was relatively small and the surveys took into account only one administration mode. This precludes a more general applicability of these findings.
The aim of the present multicentre cross-sectional survey was to explore the patients' subjective viewpoint on SIT including satisfaction, knowledge, expectations and perception in a large cohort of patients treated with either subcutaneous (SCIT) or sublingual immunotherapy (SLIT). In addition, the physicians' viewpoint (in terms of satisfaction and perception) and its association to the patients' perspectives were also explored.
MATERIALS AND METHODS
A cross-sectional observational survey was conducted across 13 specialized medical centers in North
Italy from March to September 2010. Thirteen participating physicians (allergologists, pulmonologists, dermatologists, pediatricians) invited 30 consecutive patients with allergic rhinitis with or without concomitant asthma treated with SIT to fill out a questionnaire related to their satisfaction, knowledge, expectation and perception of their treatment with SIT. Patients were invited to answer 28 questions while waiting for their control visit. The treating physicians were requested to collect clinical data of all participating patients (including disease severity, allergy sensitization, type of SIT). In addition, all physicians answered 3 questions related to their own satisfaction with the respective SIT for each patient enrolled in the survey. Both the patient and the physician were requested to complete the survey independently. The study was conducted in accordance with national legislation pertaining to confidentiality and data protection.
Patients
In all, 455 patients with allergic rhinitis with or without concomitant asthma treated with SIT (PURETHAL ® or SUBLIVAC ® HAL Allergy BV, Leiden, The Netherlands) were invited to participate in the survey. The inclusion criteria comprised the comprehension of written and spoken Italian language and the availability to participate in the survey. Exclusion criteria were the presence of evidently impaired cognitive functions and visual-auditory deficit and/or a physical inability to autonomously answer the questions.
Surveys
The questionnaires were developed by an expert panel on the basis of experience and literature review (11) (12) (13) . Prior to application, the questionnaire was tested by 10 patients and 5 physicians to ensure the word choice and content of the questions were widely understood.
The patient questionnaire consisted of 28 items evaluating the knowledge (6 questions), perception 
Statistical Analyses
It was planned to include 35 patient questionnaires from all participating physicians. Descriptive statistics were performed on demographic and clinical data and on patients'/physicians' answers to the questions. In addition, the following analyses were performed with the aim to evaluate:
-potential association between patients' education level (primary school and secondary school = low education level; high school, academic degree and postgraduate = high education level) and answers given to the survey and potential differences in answers between the two treatment modalities (SCIT and SLIT) (Chi Square Test); -correlation and concordance among patients' and physicians' answers (Spearman Rho correlation, Cohen's Kappa coefficient).
RESULTS
Of the 455 patients invited, 449 patients filled in the questionnaire. Only the questionnaires with more than a 95% completion rate (434) were considered for analysis.
Patient demographics, clinical data and duration of SIT are provided in Table 1 .
The most frequently administered allergens were grass pollen (37.1%), followed by mites (26.6%), tree pollen (17%), weed and flower pollen (9.2%), moulds (5.6%), epithelia (2%) and other allergens (2.5%) administered alone or, in a minimal percentage, in mixture.
Patients' survey
Knowledge Almost 3 out of 4 patients claimed to have heard of SIT for the first time from a physician (48.4% from a specialist and 24.4% from a GP), 14.6% from their relatives and 8.6% from the mass media (4% did not remember). Accordingly, patients' current knowledge on SIT was acquired through the information given by the specialist (86.3%), the GP (8.7%), some friends (3.1%) and the media (1.9%).
With regard to treatment effect, 7.9% of patients believed it to be immediate, 31.5% thought it would start after a few months, 28.5% after one year, 26.5% after 2 years while 5.6% declared they did not know. The majority of patients (70.6%) believed that SIT should be continued for more than two years, while lower percentages of patients indicated shorter periods (only a few months (1.4%), one year (4.2%), two years (13%), respectively) while 10.8% declared they had no idea how long the treatment would last.
Concerning their knowledge of the properties of SIT, 38.4% of patients expected it to cause side effects, 35% believed it could prevent the development of new allergies and 15.2% thought it would be necessary to stop other anti-allergy medications.
Perception
When asked to evaluate the relevance of their physician's opinion in their choice of starting with SIT on a 0-100 VAS, the patients gave a mean score of 82 (SD 21.03). Patients' perception regarding SIT treatment properties are summarized in Table 2 .
Moreover, 2.3% of patients reported that SIT caused them severe side effects, 19% reported annoying but not severe side effects, while the remainder had no side effects related to SIT.
As for additional pharmacotherapy, 81.5% of patients declared they used fewer anti-allergy drugs once they started immunotherapy, and 35% thought the benefits exceeded the costs. Almost all patients reported an improvement of their allergic condition since they started SIT (Table 3) .
Expectations
Most patients expected, when starting with SIT, that it would help them to recover from their allergy 
Satisfaction
The mean satisfaction degree for SIT effects with regard to symptoms was 74 (SD 21.5; VAS-score range 0-100), and the mean global satisfaction degree for the treatment was 77.7 (SD 21.3; VAS-score range 0-100).
No difference in the degree of satisfaction was noticed between mono-and poly-sensitized patients.
The vast majority of patients (81.5%) declared they used fewer anti-allergic medication since the start of SIT. Based on their personal experience, the majority of patients (60.7%) were convinced they would ''surely start SIT again'', 32.2% answered "I would probably start", while 2.3% would not engage on treatment with SIT again and 4.7% did not specify their answer. With regard to the administration modality, 38.4% of patients would like to change it, 39.6% would not and 22% did not answer.
Physicians' answers
Physicians' satisfaction score regarding SIT results was on mean 77.7 (SD 16.3, VAS-range 5-100).
The improvement in allergy symptoms and signs was equally positive and similar to the patient reported answers (Table 3 ). Over 90% of physicians answered they would prescribe the same type of SIT for that specific patient again (68% of them would surely prescribe it, 27.5% probably) whereas 1.7% declared that they would not (1.2% probably not and 0.5% surely not) and 2.8% did not know.
Concordance between patients' and physicians' answers
There was a significant correlation between patients' and physicians' satisfaction scores regarding SIT, both in the SCIT group (r = 0.612, p <0.001) and in the SLIT group (r = 0.608, p <0.001) (Figure 1 ).
Moreover, physicians and patients expressed a significant level of agreement in judging the clinical changes after starting SIT treatment, both in the SCIT group (Kappa = 0.318, p <0.001) and the SLIT group (Kappa= 0.380, p <0.001).
Differences in answers based on patients' educational level
For this subgroup analysis, patients were divided into two groups according to their educational level (high or low) at the start of the survey. In the entire survey, only for the question "In your opinion, can SIT prevent the development of new allergies?" an association between education level was found (Chi-Square 4409, p= 0.029) where a higher percentage of patients with a high education agreed with this statement (64% vs. 53%).
Difference in answers between the two SIT formulations (SCIT versus SLIT)
The majority of patients were taking SLIT (313, 74%) while 110 patients were administered SCIT. A subgroup analysis based on the different allergens used for SIT was not possible due to too low numbers in one or more subgroups.
DISCUSSION
This real life cross-sectional survey aimed to evaluate the personal perspectives during treatment with either subcutaneous or sublingual SIT in a large number of Italian patients recruited from various medical centres. To this end, a survey consisting of 28 questions assessing patient's satisfaction, knowledge, expectations and perception, was developed by an expert panel. The survey was readily accepted by the patients: 449 out of 455 decided to participate, and, it was deemed easy to understand and to complete. In addition, correspondence with the physician's view was assessed. Our data confirm and extend previously published experience with SIT (8, 10, 14) .
Allergen specific immunotherapy is a valuable causal treatment for respiratory allergies. However, it is a lengthy therapy and not without certain risks. Therefore, patient knowledge should be adequate when following SIT therapy. Although over 70% of patients showed adequate knowledge of SIT, this survey identified some gaps and misconceptions in patients, independent of their educational level. The comparison between patient's evaluations of SLIT and SCIT revealed that SLIT was frequently considered easier to take and superior in terms of costs/benefits, although a similar degree of satisfaction was reported in both treatment groups..
Our study should be viewed in the light of its limitations. The cross--sectional design, the use of self--report tools, the differences in clinical and therapeutic aspects (including the presence or absence of any co--sensitisations or concomitant asthma, administration modality, treatment duration) can be considered as the main weak points. Moreover, our results refer to the patients' personal point of view with regards to a specific product and treatment regimen and thus cannot be generalized to other SIT products or to other administration modalities. We acknowledge that the correlation we found between patient and physician satisfaction towards treatment may be somewhat influenced by the doctor -patient relationship. In patients with a chronic condition, the choice of treatment by the treating physician may positively affect the patient's view and satisfaction towards this treatment. Conversely, a patient's satisfaction towards treatment will positively affect the physician's judgement. However, patients and physicians scored the questions independently, and since in our study strong correlations between patient and physician satisfaction scores were found over the entire VAS scale reflecting several aspects of satisfaction, we believe this reinforces the positive value of our findings.
The main strength is that data collection was performed in real life in a large patient population, providing relevant data for clinical management of patients receiving SIT: this is in accordance with the most recent guidelines, emphasizing the importance of the patient's point of view on treatment. Our results can be considered as preliminary data that must be followed by further research involving other countries and longitudinal samples, before more solid conclusions can be drawn regarding the patients' viewpoint about SIT. The information provided by the specialist
The information provided by the general practitioner
The information you got from newspapers, television, internet
The information you got from friends
10) When you decided to start SIT, what did influenced your choice?
The possibility of reducing the drugs for allergy treatment
The ability to act on the disease rather than on symptoms
The ability to prevent the development of new allergies Dissatisfaction with the drugs I had used 
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

18) Has SIT caused to you not severe but annoying side effects?
No Yes (please indicate which side effects)
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
19)
Since you started being treated with SIT, have you used less drugs for allergy? not at all very much
No Yes (please indicate which drugs) ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
20
